Skip to content
lifestyle.cosmeticsurgeryinsider.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Kymera Therapeutics, Inc.
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
March 10, 2026
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
February 24, 2026
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
February 19, 2026
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
February 4, 2026
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
January 29, 2026
←
Previous Page
1
2